Analyst consensus rating
Amneal Pharmaceuticals Analyst Rating: none
AMRX is rated none by 4 analysts with a $20.75 target. As of 2026-08-22.
Direct answer
Amneal Pharmaceuticals's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $20.75.
Forecast evidence checked August 22, 2026.
Get free Amneal Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $17.91
- Average price target
- $20.75
- High price target
- $25.00
- Low price target
- $16.00
- Low target gap
- -10.7%
- Target upside
- +15.9%
- High target gap
- +39.6%
- Target range width
- 50.3%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- August 22, 2026
- Valid through
- August 29, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Amneal Pharmaceuticals?
Amneal Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $20.75.
How far are Amneal Pharmaceuticals's low and high targets from the recorded price?
The low target implies -10.7%, while the high target implies +39.6%.
How many analysts are included in Amneal Pharmaceuticals's consensus?
The verified consensus includes 4 analysts.
How is Amneal Pharmaceuticals's target upside or downside calculated?
The average target of $20.75 is divided by the recorded price of $17.91, then one is subtracted to produce +15.9%. This does not guarantee a future return.
When was Amneal Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-22. The dataset is valid through 2026-08-29.